The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia
- PMID: 34782300
- DOI: 10.1016/j.resinv.2021.09.012
The current definition, epidemiology, animal models and a novel therapeutic strategy for aspiration pneumonia
Abstract
In the 21st century, aspiration pneumonia (ASP) is very common in older patients, and has a high mortality rate. ASP is diagnosed following confirmation of inflammatory findings in the lungs and overt aspiration or the existence of dysphagia. It is dominant in hospitalized community-acquired pneumonia (CAP), nursing and healthcare-associated pneumonia (NHCAP), and hospital-acquired pneumonia (HAP). The incidence of ASP is increasing every year. The human and experimental animal data revealed that micro-aspiration due to dysphagia during the night is the central mechanism of ASP. Therefore, the precise assessment of swallowing function is the key to diagnose ASP. From a therapeutic point of view, an appropriate administration of antibiotics, as well as a comprehensive approach for dysphagia plays a pivotal role in the prognosis and recovery from ASP. The non-pharmacologic approach, including swallowing rehabilitation and oral care, and a pharmacologic approach including ACE inhibitors and bronchodilators, are essential modalities for treatment and prevention of ASP. The clinical data of NHCAP provides us with a promising treatment strategy for ASP.
Keywords: Animal model; Aspiration pneumonia; Dysphagia; Micro-aspiration; Swallowing function test.
Copyright © 2021 The Author. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Conflict of Interest Shinji Teramoto has received a speaker honorarium from Nippon Boehringer Ingelheim. Co, AstraZeneca Co. and KYORIN Pharmaceutical Co.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
